

How to put this into clinical practice?

JY Blay

Medical Oncology, Lyon

EORTC

Conticanet, EuroSARC

We need

- To improve compliance to CPGs
- Reference centers
- More simple academic clinical trials
- Extensive database and series of patients and tumor samples
- To integrate research into routine

How can
YOU help?

Sign
our petition
NOW...

...and ask FRIENDS,
COLLEAGUES and
CONTACTS...

...to support
this initiative
by SIGNING UP
too!

The European Action Against Rare Cancers is a joint initiative based on a partnership between the European Society for Medical Oncology (ESMO), the European Organisation for Rare Diseases (Eurordis), the European Cancer Patient Coalition (ECPC), Conticanet, the Association of European Cancer Leagues (ECL), the Chronic Myeloid Leukaemia Support Group, the International Brain Tumour Alliance (IBTA), Orphanet, the Chronic Myeloid Leukaemia Advocates Network, the European Institute of Oncology (EIO) and the Fondazione IRCCS Istituto Nazionale dei Tumori, as well as Novartis Oncology as the founding sponsor.

The organisations collaborate as equal partners and all decisions are made on the basis of consensus. The initiative is moreover supported by eight corporate organisations.

For more information about this European initiative, please visit our Web site:
www.rarecancers.eu

or contact us:
European Action Against Rare Cancers
c/o Robert Schaefer

Brunnenstrasse 178/179
10119 Berlin, Germany
T +49 (0)30 288 797 55
F +49 (0)30 288 797 66

schaefer.robert@esmo.org
www.rarecancers.eu



Collaborating Partners:




Initiating Sponsors:



**RARE CANCERS:
MORE COMMON
THAN
YOU THINK!**

☒ Sign the call to
ACTION AGAINST RARE CANCERS

www.rarecancers.eu



European Action Against Rare Cancers



Menu

[Home](#)[Charter](#)[Survey](#) →[Export](#) →[Patient](#) →[Audit](#) →[Online Help](#) →

Welcome to conticabase

The CONTICANET database and tumour bank

This database contains anonymised information describing the tumour, treatment and follow-up as well as tumour sample availability and molecular biology analyses for mesenchymal tumours except GIST and bone tumours.

The tool can be used as a local center database thanks to its **rules for access to patient data and material**. It will be maintained and updated centrally. Please follow this **this link** to fill the account application form

The query tool allows users to ask questions about the overall content of the database in order to evaluate the feasibility of specific collaborative studies.

We hope this database will become an important tool for increasing our knowledge on these rare tumours and for developing joint research programmes.

Website requirements

This website has been designed for both **Firefox 3** (advised) and **Internet Explorer 7** (or older versions). Please note that some features may not work correctly with other web browsers.

Content overview


conticabase currently contains the following data from **26** out of the **43** registered centres :

- **4804** Patients
- **4826** Tumours
- **5699** Samples (**5493** Paraffins and **2600** Frozen)

Networks and PAGs

- Health care Networks
- **Reference centers**, within quality control programs. They improve health care and they improve accrual in trials as well as clinical quality within clinical trials.
- **Patient information about trials** (what they are, where they are available). There is even a greater added value for the today patient in entering a trial.

18 SPAEN Full Members



A World Sarcoma Network is needed



Strategies

- Simple prospective clinical trials
- Smart retrospective studies
 - e.g. long responders
- Generate attractive hypotheses

The World Sarcoma Network (2009)

Studies pipeline

- nilotinib in PVNS with t(1,2) M-CSF-col6A3 fusion gene
- mTOR inhibitors in PEComas, and in tumours of the TSC complex
- Aplidin in Dedifferentiated Liposarcomas with JUNK overexpression
- Alk inhibitors in inflammatory myofibroblastic tumours with Alk amplification and over expression
- IGF1R inhibitors in GIST with IGF1R over-expression and amplification
- MDM2 inhibitors (nutlin3a) in WDLPS with MDM2 amplification
- MET inhibitors in sarcomas with translocation involving fusion genes encoding for abnormal transcription factors (ASPS, CCS)
- VEGFR2 inhibitors in ASPS

Strategies

- Simple prospective clinical trials
- Smart retrospective studies
 - e.g. long responders
- Generate attractive hypotheses

How to improve collaboration ?

Perimeter

National
European
Worldwide

Structure

Centre
Group
Intergroup
EU (EORTC)

Funding

National- x-fold
EU FPs
Partnership

Patient
Advocacy
Groups

Partnership
with pharma
industry

**Thank you for your attention
and your participation**

